Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study (original) (raw)
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study
Alessandro Vatrella
medRxiv (Cold Spring Harbor Laboratory), 2024
View PDFchevron_right
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
Alessandro Vatrella
Drug Design, Development and Therapy, 2018
View PDFchevron_right
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Stefano Del Giacco
Frontiers in allergy, 2022
View PDFchevron_right
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
Alessandro Vatrella
Journal of Clinical Medicine, 2023
View PDFchevron_right
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Anahí Yáñez
The Lancet Respiratory Medicine, 2018
View PDFchevron_right
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
Mitsuo Hashimoto
BMC Pulmonary Medicine, 2019
View PDFchevron_right
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
Alessandro Vatrella
Biomedicines, 2022
View PDFchevron_right
Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
Francesco Menzella
Journal of Asthma and Allergy, 2021
View PDFchevron_right
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
Pasquale Tondo
Journal of Clinical Medicine
View PDFchevron_right
The clinical profile of benralizumab in the management of severe eosinophilic asthma
Francesco Menzella
Therapeutic advances in respiratory disease, 2016
View PDFchevron_right
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects
Jorge Máspero
Therapeutic Advances in Respiratory Disease, 2017
View PDFchevron_right
Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma
Ken Ohta
Allergology international : official journal of the Japanese Society of Allergology, 2017
View PDFchevron_right
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
Carlos Martínez-Rivera
Respiratory Research
View PDFchevron_right
Eosinophilic Asthma
fozia masood
Asthma and Lung Biology [Working Title], 2019
View PDFchevron_right
A Case Study Showing Benralizumab’s Effectiveness in Treating Uncontrolled Severe Eosinophilic Asthma that is Resistant to Omalizumab
Stelphy Stephen
International journal of science and healthcare research, 2022
View PDFchevron_right
Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma
William Calhoun
Expert Opinion on Biological Therapy, 2011
View PDFchevron_right
Eosinophilic inflammation in cough variant asthma
Akio Niimi
The European respiratory journal, 1998
View PDFchevron_right
Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)
rosa feijoo
Journal of Asthma and Allergy
View PDFchevron_right
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
Alessandro Vatrella
Journal of Asthma and Allergy
View PDFchevron_right
Biologic therapy in the management of asthma
William Calhoun
Current Opinion in Allergy and Clinical Immunology, 2016
View PDFchevron_right
Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
Maria Pia Foschino
Frontiers in Pharmacology, 2021
View PDFchevron_right
Impact of benralizumab on asthma control, asthma-related quality of life and lung function in patients with poorly controlled eosinophilic asthma: A systematic review and meta-analysis
Masoud Mahdavian
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018
View PDFchevron_right
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
Antolín Viña
Drugs
View PDFchevron_right
Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
Carlos Martínez-Rivera
BMC Pulmonary Medicine, 2021
View PDFchevron_right
The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)
Botond Mátyás
Journal of Interdisciplinary Medicine, 2021
View PDFchevron_right
Real world effectiveness of benralizumab on respiratory function and asthma control
Silvia Capobelli
Multidisciplinary Respiratory Medicine, 2021
View PDFchevron_right
Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis
stefano baglioni
Respiratory Medicine and Research, 2020
View PDFchevron_right
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
Jessica Beltran
Allergy
View PDFchevron_right
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
DR MUNISH SAROCH
Current medical research and opinion, 2017
View PDFchevron_right
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Ewa Springer
The Lancet. Respiratory medicine, 2017
View PDFchevron_right
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study
Alessandro Vatrella
International Journal of Molecular Sciences, 2023
View PDFchevron_right
Novel Biological Therapies for Severe Asthma Endotypes
Alessandro Vatrella
Biomedicines, 2022
View PDFchevron_right
Infectious Diseases and Asthma. Preface
Shyam Mohapatra
Immunology and allergy clinics of North America, 2010
View PDFchevron_right
Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
Antolín Viña
BMC Pulmonary Medicine, 2021
View PDFchevron_right